Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Abstract In March 2013, the Acromegaly Consensus Group met to revise and update
guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

" Objective: The Acromegaly Consensus Group reconvened in November 2007 to update
guidelines for acromegaly management. Participants: The meeting participants comprised …

AACE= American Association of Clinical Endocrinologists; BEL=“best evidence” level;
BMD= bone mineral density; CPAP= continuous positive airway pressure; CPG= clinical …

Context: Cabergoline is widely considered to be poorly effective in acromegaly. Objective:
The aim of this study was to obtain a more accurate picture of the efficacy of cabergoline in …